Clinical Trials Logo

Clinical Trial Summary

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic hereditary kidney disease in humans. ADPKD may affect all the generations of the ADPKD family and the probability of ADPKD is 50% in the second generation for each gender. It has been confirmed that PKD1 and PKD2 are two pathogenic genes of ADPKD. Nowadays, the investigators have established an effective gene detection technology platform for PKD1/2 gene with long fragment PCR and next generation sequencing. First, the investigators performed genetic testing in patients with clinically diagnosed ADPKD and strong fertility desire, but afraid of hereditary risk. Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators successfully screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. When the baby is born, using umbilical cord blood gene detection, the investigators confirmed that the neonates do not inherit genetic defects form parents. The investigators have succeeded in one couple. The investigators design a multicenter clinical trial to confirm those procedures efficacy and safety.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02948179
Study type Interventional
Source Shanghai Changzheng Hospital
Contact
Status Completed
Phase N/A
Start date September 2, 2016
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT02055079 - Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease Phase 3